September 20, 2019 11:12 AM EDTUpdated September 21, 05:54 PM
Peer Review

Chris Roberts jumps back in­to biotech with CSO gig at Black Di­a­mond; Trou­bled Five Prime ap­points in­ter­im CEO

ENDPOINTS

→ Af­ter spend­ing two years as en­tre­pre­neur-in-res­i­dence at SR One — the ven­ture arm of his for­mer em­ploy­er, Glax­o­SmithK­line

Endpoints News

Sign up to read this article for free.

Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.

BECOME A PREMIUM SUBSCRIBER
TRENDING NOW

Pa­tient dies in Neu­ro­gene's Rett syn­drome study

Lil­ly's board un­der­goes more changes; Mer­ck strat­e­gy chief joins Roger Perl­mut­ter at Eikon

Sur­round­ed by AI bio gi­ants, tiny start­up Nabla Bio makes de no­vo an­ti­bod­ies look more like drugs 

Halozyme with­draws Evotec ac­qui­si­tion pro­pos­al af­ter biotech is 'un­will­ing to en­gage'

From vac­cines to psy­che­delics, five drug­mak­ers on what could change un­der a Trump ad­min­is­tra­tion

sponsored

Are pro­grams with com­pound­ed GLP-1s safe for your pop­u­la­tion?

A service from the Financial Times